Skip to content

INJECTABLE BULKING AGENT FOR MALE URINARY INCONTINENCE TREATMENT: A MULTI-CENTRE EFFECTIVENESS AND SAFETY PILOT STUDY

INJECTABLE BULKING AGENT FOR MALE URINARY INCONTINENCE TREATMENT: A MULTI-CENTRE EFFECTIVENESS AND SAFETY PILOT STUDY - Opsys bulking agent for male incontinence

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON43352
Enrollment
30
Registered
2016-06-16
Start date
2016-08-15
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

incontinence urine loss

Interventions

Opsys will be implanted using a video endoscope with a transurethral injection needle.

Sponsors

Ziekenhuisgroep Twente
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: * Male, aged between 18 and 85 years old. * Subject remains dry at night. * Ability to voluntarily stop micturition. * Stress Urinary Incontinence caused by Intrinsic sphincter deficiency ISD secondary to a post RP, refractory to conservative treatment with a post-operative of at least 12 months. * Urinary incontinence classified as minimal to mild incontinence level by a 24 h pad weight test mentioned in the clinical data (less than 30 g per day urine loss on 24 h pad weight test), and quality of life has deteriorated so as to require surgery as a method of treatment. * Consent informed signed.

Exclusion criteria

Exclusion criteria: Exclusion criteria: * Post-prostatectomy radiotherapy or brachytherapy. * Subject radiated as treatment of Prostate Cancer, being this interstitial or external, neo-adjuvant, therapeutic or adjuvant. * Bladder neck sclerosis or urethral stricture. * Detrusor hyperactivity. * Lower Urinary Tract Infections * Urge Incontinence.

Design outcomes

Primary

MeasureTime frame
Primary endpoint: * Two 24 h Pad Weight Test (PWT)

Secondary

MeasureTime frame
Secondairy endpoints: * 48 h voiding diary to record micturition episodes * Complete Urinalysis with Urine culture * Urodynamic evaluation: o Uroflowmetry o Urethral pressure (leak point pressure measurement before and after surgery) o Cystometric test o Post Void Residual Measurement * International Consultation on Incontinence Questionnaire * Short Form (ICIQ-UI-SF) * Incontinence Impact Questionnaire * Short Form (IIQ-7) * Patient Global Impression of Improvement (PGI-I) * Urogenital Distress Inventory * Short Form (UDI-6)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)